Breaking News


Patient-reported outcomes in psoriasis patients treated with continuous or paused long-term etanercept


A 54-week, multicenter, European, open-label study in patients with mild-moderate psoriasis randomized patients to continuous etanercept therapy (25 mg s.c. twice weekly) or paused therapy (50 mg etanercept s.c. twice weekly 12 weeks or less) until a Physicians Global Assessment (PGA) score of 2 or less was attained. Treatment was restarted (25 mg s.c. twice weekly) if psoriasis returned. The patient-reported outcomes (PROs) measured comprised the Dermatology Life Quality Index (DLQI), the EuroQoL-5D, the Hospital Anxiety and Depression Scale (HADS) and the Short-Form 36 (SF-36) Vitality subscale. Both regimens provided improvement in PRO measures. There were significant differences between the DLQI and EQ-5D utility and VAS scores in favor of continuous therapy ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list